FindTrial
Sign In

Myeloablative conditioning regimen

DRUG4 trials

Sponsors

Masonic Cancer Center, University of Minnesota, Stanford University, Randy Windreich, Hannah Choe, MD

Conditions

Acute LeukemiaAcute Lymphoblastic Leukemia (ALL)Acute Myelogenous LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Chediak-Higashi SyndromeChronic Myelogenous LeukemiaChronic Myelomonocytic Leukemia

Phase 1

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
CompletedNCT01660607
Stanford UniversityAcute Leukemia, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia +6
Start: 2012-02-09End: 2023-12-20Updated: 2025-08-19

Phase 2

T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
TerminatedNCT00176826
Masonic Cancer Center, University of MinnesotaChediak-Higashi Syndrome, Griscelli Syndrome, Hematologic Diseases +4
Start: 2000-09-30End: 2015-08-31Updated: 2018-01-23
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
CompletedNCT02626715
Randy WindreichAcute Myeloid Leukemia (AML), Hematopoietic Stem Cell Transplant (HSCT), Myelodysplastic Syndrome (MDS)
Start: 2015-09-04End: 2023-04-12Updated: 2024-07-16
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RecruitingNCT07249346
Hannah Choe, MDChronic Myelomonocytic Leukemia, Leukemia, Myelodysplasia
Start: 2026-01-14End: 2027-06-01Target: 124Updated: 2026-09-02

Related Papers

Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL
Blood2025-11-03
Donor regulatory T-cell therapy to prevent graft-versus-host disease
Blood2025-01-1026 citations
Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD
Blood Advances2023-12-1322 citations
Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
Blood2022-11-1517 citations
S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES
HemaSphere2022-06-011 citations
Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study
Blood2021-11-0510 citations
Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors
Blood2021-11-05
Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants
Blood2020-11-049 citations
Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients
JCI Insight2019-05-1579 citations